X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42) 42
female (33) 33
male (29) 29
aged (28) 28
middle aged (28) 28
index medicus (27) 27
risk factors (26) 26
cardiac & cardiovascular systems (21) 21
abridged index medicus (15) 15
myocardial infarction (14) 14
medicine, general & internal (13) 13
risk (13) 13
stroke (13) 13
cardiovascular diseases (12) 12
mortality (12) 12
drug therapy (10) 10
heart failure (10) 10
care and treatment (9) 9
cerebral infarction (9) 9
double-blind method (9) 9
follow-up studies (9) 9
heart attacks (9) 9
patients (9) 9
prevention (9) 9
treatment outcome (9) 9
atrial fibrillation (8) 8
cardiovascular disease (8) 8
clopidogrel (8) 8
coronary artery disease (8) 8
dosage and administration (8) 8
prognosis (8) 8
therapy (8) 8
atherosclerosis (7) 7
cardiovascular diseases - mortality (7) 7
cardiovascular diseases - prevention & control (7) 7
disease (7) 7
heart (7) 7
inflammation (7) 7
stroke - prevention & control (7) 7
adult (6) 6
aspirin (6) 6
echocardiography (6) 6
europe - epidemiology (6) 6
guidelines (6) 6
heart diseases (6) 6
kaplan-meier estimate (6) 6
management (6) 6
myocardial infarction - drug therapy (6) 6
secondary prevention (6) 6
stroke - etiology (6) 6
ticagrelor (6) 6
acute coronary syndromes (5) 5
anticoagulants (5) 5
bleeding (5) 5
cardiac and cardiovascular systems (5) 5
cardiology (5) 5
clinical medicine (5) 5
clinical trials (5) 5
diagnosis (5) 5
health risk assessment (5) 5
hypertension (5) 5
ischemia (5) 5
kardiologi (5) 5
klinisk medicin (5) 5
medical and health sciences (5) 5
medicin och hälsovetenskap (5) 5
medicine (5) 5
myocardial infarction - mortality (5) 5
prospective studies (5) 5
risk assessment (5) 5
acute coronary syndrome (4) 4
acute myocardial-infarction (4) 4
aged, 80 and over (4) 4
american-college (4) 4
angina (4) 4
angina pectoris (4) 4
anticoagulation (4) 4
arteriosclerosis (4) 4
association task-force (4) 4
atrial fibrillation - complications (4) 4
atrial fibrillation - drug therapy (4) 4
benzaldehydes - adverse effects (4) 4
blood pressure (4) 4
cardiac arrhythmia (4) 4
cardiovascular diseases - epidemiology (4) 4
complications and side effects (4) 4
coronary disease (4) 4
death (4) 4
diabetes (4) 4
dose-response relationship, drug (4) 4
drug therapy, combination (4) 4
drugs (4) 4
epidemiology (4) 4
europe (4) 4
familial hypercholesterolemia (4) 4
heart attack (4) 4
heart-disease (4) 4
incidence (4) 4
infarction (4) 4
lipids (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 22, pp. 2248 - 2261
In this clinical trial, rosuvastatin was compared with placebo in elderly patients with systolic, ischemic heart failure. Although rosuvastatin significantly... 
MORTALITY | SURVIVAL | MEDICINE, GENERAL & INTERNAL | DESIGN | THERAPY | EVENTS | MYOCARDIAL-INFARCTION | CHOLESTEROL | DISEASE | PRAVASTATIN | STATINS | Single-Blind Method | Follow-Up Studies | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Systole | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Heart Failure - etiology | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Heart Failure - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Ischemia - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Heart failure | Placebos | Rosuvastatin | Dosage and administration | Drug therapy | Comparative analysis | Cardiovascular disease | Heart attacks | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Myocardial Ischemia | epidemiology | Pyrimidines | Heart Failure | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | complications | Fluorobenzenes | Hospitalization | etiology | statistics & numerical data | Sulfonamides | mortality | adverse effects | therapeutic use
Journal Article
The Lancet, ISSN 0140-6736, 12/2016, Volume 388, Issue 10062, pp. 2895 - 2903
Journal Article
Open Cardiovascular Medicine Journal, ISSN 1874-1924, 2014, Volume 8, Issue 1, pp. 35 - 42
Post-marketing observational studies are valuable for establishing the real-world effectiveness of treatment regimens in routine clinical practice as they... 
Irbesartan | Valsartan | Candesartan | Angiotensin receptor blockers | Blood pressure | Eprosartan | Observational studies | Systemic Coronary Risk Evaluation
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
JAMA, ISSN 0098-7484, 09/2014, Volume 312, Issue 10, pp. 1006 - 1015
Journal Article